SCHEMBL6469138

SCHEMBL6469138

O=C(NNC(=O)c1ncc(C(F)(F)F)cc1Cl)c1ccccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.56
HPGD P15428 1/20 0.56
GAA P10253 3/20 0.56
KDM4E B2RXH2 3/20 0.56
POLB P06746 2/20 0.56
ALDH1A1 P00352 5/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
RPS6KA3 P51812 1/20 0.51
P2RX1 P51575 2/20 0.49
P2RX4 Q99571 1/20 0.49
P2RX7 Q99572 1/20 0.49
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449845 0.82 TMPRSS4 (0.55) GLAHPGDGAAKDM4EPOLB
SCHEMBL18668519 0.77 ALDH1A1 (0.57) GLAHPGDGAAKDM4EPOLB
SCHEMBL17111063 0.75 ALDH1A1 (0.56) GLAHPGDGAAKDM4EALDH1A1
SCHEMBL18668549 0.74 ALDH1A1 (0.62) GLAHPGDGAAPOLBALDH1A1
SCHEMBL15929894 0.72 HTT (0.58) GLAHPGDKDM4EALDH1A1MEN1
SCHEMBL707320 0.72 ALDH1A1 (0.63) GLAHPGDGAAKDM4EALDH1A1
SCHEMBL7827542 0.72 GAA (0.77) GLAHPGDGAAKDM4EPOLB
SCHEMBL27515324 0.72 GLA (0.58) GLAHPGDGAAKDM4EPOLB
SCHEMBL19976665 0.72 GLA (0.52) GLAHPGDGAAKDM4EPOLB
SCHEMBL16761935 0.72 PTGS1 (0.58) GLAHPGDGAAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC GLA 2259/4885HPGD 258/4885GAA 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.